Drug Trial Radar · NCT07583810
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Sep 25, 2030
Study completion Sep 25, 2030
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib in combination with rituximab may be safe, tolerable and/or effective in treating patients with marginal zone lymphoma.
Conditions
- Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
- Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
- Marginal Zone Lymphoma
- Nodal Marginal Zone Lymphoma
- Splenic Marginal Zone Lymphoma
- Lymphoma
- Extranodal Marginal Zone Lymphoma
Interventions
Biopsy ProcedureProcedure
Undergo tissue biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo CT or PET/CT
Magnetic Resonance ImagingProcedure
Undergo MRI
NemtabrutinibDrug
Given PO
Positron Emission TomographyProcedure
Undergo PET/CT
RituximabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of unacceptable toxicity (Safety lead-in)Time frame: During cycle 1 (cycle length = 28 days)
- Complete response (CR) rate (Phase 2)Time frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.